BMS 986166

Drug Profile

BMS 986166

Alternative Names: BMS-986166

Latest Information Update: 13 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bristol-Myers Squibb
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ulcerative colitis

Most Recent Events

  • 30 Jan 2017 Bristol Myers Squibb plans a phase I trial in Healthy volunteers in USA (PO, Liquid) (NCT03038711)
  • 01 Jan 2017 Bristol-Myers Squibb initiates enrolment in a phase I trial for Healthy volunteers in USA (PO, Liquid) (NCT03038711)
  • 01 Jul 2016 Phase-I clinical trials in Ulcerative colitis (In volunteers) in USA (PO) (NCT02790125)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top